Koers Allarity Therapeutics, Inc. Nasdaq Stockholm
Aandelen
ALLR
US0167441049
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 309K 3,34 mln. 287K |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -16 mln. -173 mln. -14,87 mln. | Nettowinst (verlies) 2025 * | -28 mln. -303 mln. -26,02 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,38
x | K/w-verhouding 2025 * |
-0,64
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 100% |
Recentste transcriptie over Allarity Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Jensen
FOU | Founder | 46 | 01-06-20 |
Joan Brown
DFI | Director of Finance/CFO | 71 | 21-09-21 |
Chief Tech/Sci/R&D Officer | 63 | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 56 | 01-10-22 | |
Thomas Jensen
FOU | Founder | 46 | 01-06-20 |
Joseph Vazzano
BRD | Director/Board Member | 40 | 01-08-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |